BPLPHARMA · NSE
Bharat Parenterals Limited
₹1,898
+20.00% (+₹316.3)
Prev. close
₹1,581.7
Volume
35,202
Delivery %
54.3%
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Bharat Parenterals Limited
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers research, development and manufacture of pharmaceutical formula ons, including sterile injectable products, oral liquid formula ons, prefilled syringes, other specialty, and eye drops. Bharat Parenterals Limited was incorporated in 1992 and is based in Vadodara, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Bharatkumar Rameshchandra Desai
Headquarters
Vadodara
Employees
404
Website
bplindia.inExchange
View on NSE ↗Key stats
Dividend yield
0.05%
EPS (TTM)
₹-22.40
Beta (5Y monthly)
0.74
Shares float
14.50 L
EPS · quarter ended Jun 2026
₹1.46
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.2% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹204.64 Cr | ₹212.01 Cr | ₹217.56 Cr | ₹257.05 Cr | ₹335.48 Cr | ₹343.05 Cr | |
| EBITDA | ₹33.92 Cr | ₹35.43 Cr | ₹31.62 Cr | ₹30.92 Cr | ₹13.29 Cr | ₹24.29 Cr |
| ₹20.31 Cr | ₹20.81 Cr | ₹16.44 Cr | ₹14.52 Cr | ₹-12.63 Cr | ₹-8.19 Cr | |
| Diluted EPS | ₹35.59 | ₹36.67 | ₹28.4 | ₹24.94 | ₹-19.26 | ₹-11.88 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | ₹198.65 Cr | ₹226.06 Cr | ₹350.34 Cr | ₹504.04 Cr | ₹648.53 Cr | ₹613.30 Cr | |
| — | ₹12.24 Cr | ₹17.75 Cr | ₹49.74 Cr | ₹157.58 Cr | ₹180.20 Cr | ₹146.11 Cr | |
| Stockholders' equity | — | — | — | ₹182.80 Cr | ₹197.27 Cr | ₹330.67 Cr | ₹322.23 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹21.66 Cr | ₹-4.71 Cr | ₹-27.25 Cr | ₹38.36 Cr | |
| Investing cash flow | — | — | ₹-77.82 Cr | ₹-104.78 Cr | ₹-137.39 Cr | ₹9.32 Cr |
| — | — | ₹60.60 Cr | ₹110.43 Cr | ₹156.37 Cr | ₹-47.05 Cr | |
| Capital expenditure | — | — | ₹-91.60 Cr | ₹-104.30 Cr | ₹-29.08 Cr | ₹-39.93 Cr |
| End cash position | — | — | ₹7.84 Cr | ₹8.78 Cr | ₹44.28 L | ₹1.20 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| Bharat Parenterals Limited | — | ₹1,581.7 | — | — | -2.5% | 0.45 | +2.3% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Bharat Parenterals hits 20% upper circuit on fundraise plan | Tap to know more | Inshorts
Bharat Parenterals shares rose 20% to a 52-week high after the company announced its board will meet on September 29 to consider a preferential issue of equity shares. This marks a 25% gain over three trading sessions. The specific amount of the proposed fundraise was not disclosed.
Bharat Parenterals shares rally 25% in three sessions; Here is why stock is rising
upstox.com · 3 days ago